The Epstein-Barr virus-encoded early protein, BHRF1, is a structural and functional homologue of the anti-apoptotic protein, Bcl-2. There is accumulating evidence that BHRF1 protects a variety of cell types from apoptosis induced by various external stimuli. To identify specific proteins from normal epithelial cells that interact with BHRF1 and that might promote or inhibit its anti-apoptotic activity, we screened a yeast two-hybrid cDNA library derived from human normal foreskin keratinocytes and identified a cellular gene encoding human prenylated rab acceptor 1 (hPRA1). The interaction of hPRA1 with BHRF1 was confirmed using GST pull-down assays, confocal laser scanning microscopy and co-immunoprecipitation. Two regions of PRA1, aa 30-53 and the carboxyl-terminal 21 residues, are important for BHRF1 interactions and two regions of BHRF1, aa 1-18 and aa 89-142, including the Bcl-2 homology domains BH4 and BH1, respectively, are crucial for PRA1 interactions. PRA1 expression interferes with the anti-apoptotic activity of BHRF1, though not of Bcl-2. These results indicate that the PRA1 interacts selectively with BHRF1 to reduce its anti-apoptotic activity and might play a role in the impeding completion of virus maturation.
INTRODUCTION
Apoptosis, also called programmed cell death, is an essential and highly conserved and controlled physiological process. It plays an important role in various biological events mitochondria (13, 22) . Mitochondria play a pivotal role in the apoptotic signaling pathway by releasing apoptogenic factors from the mitochondrial intermembrane space into the cytoplasm, such as cytochrome c (23) which binds to Apaf-1 and activates caspase-9, thereby eliciting the downstream caspase cascade and inducing apoptosis (13, 22, 24) . It has been shown that the anti-apoptotic Bcl-2 family proteins prevent cytochrome c release and in turn prohibit the activation of the caspase cascade and apoptosis (25) .
In the face of the tremendous diversity of viruses, higher vertebrates have evolved general defense mechanisms to control viral infection. The initiation of apoptosis by host cells is one such innate host response that can quickly and efficiently remove virus-infected cells, so limiting virus reproduction and total viral burden, reducing or eliminating the dissemination of progeny virus in the host, and minimizing the effects of virus infection and the susceptibility to mutational adaptation by virus (26) . Thus, the interaction of specific host cellular proteins with viral proteins that promote proliferation or protect cells from apoptosis is a key determinant in influencing the dynamic equilibrium between life and death and the extent of virus infection.
The Epstein-Barr virus (EBV)-encoded anti-apoptotic protein BHRF1 is of particular interest in this regard. EBV is a ubiquitous human gamma herpesvirus which infects B lymphocytes, where it establishes latent infections, and stratified squamous epithelium, where it undergoes productive replication (27) and increases the susceptibility of these cells to oncogenic transformation. EBV is closely associated with a variety of human diseases, including was cloned into vector pUHD10.3 and its expression could be turned on by a holo-transactivator, composed of a transactivator and a co-transactivator. The transactivator was expressed from plasmid pUHD172-1neo and the co-transactivator was provided in the form of doxycycline (Dox) , a tetracycline derivative.
Vector pcDNA3.1(+) (Invitrogen, Groningen, The Netherlands) was used to express target proteins constitutively. An EBNA-1 tag (aa 408-446 from EBV nuclear antigen-1) from pCF7 (52) was inserted into the vector for convenient identification of the target protein, resulting in the generation of plasmid pcDNA3.1/NA-1. For constitutive expression of BHRF1, wild type (WT) NBHRF1 and a mutant encoding aa were inserted into pcDNA3.1/NA-1 in frame with the EBNA-1 tag.
Plasmids expressing rat PRA1 (rPRA1) and polypeptides derived from it were generously provided by J. K. Ngsee (University of Ottawa, Ottawa, Canada) (53). The protein products included WT rPRA1 and polypeptides comprising aa 1-110, 1-164, 30-185 and 54-185, in each case as a fusion protein with a GAL4 activation domain (GAL4-AD) in pGAD424 vector (Clontech, Palo Alto, Calif.) (53). DNA fragments encoding the WT protein and aa 1-164, 30-185 and 54-185 of rPRA1 were subcloned into vector pcDNA3-HA to generate an amino-terminal hemagglutinin (HA)-tag when expressed in mammalian cells.
Human PRA1 (hPRA1) plasmid, pGAD-hPRA1, was a gift from C. B. Bruni (University of Napoli, Napoli, Italy) (47) and had the entire gene fused to GAL4-AD in vector pGAD10
by guest on http://www.jbc.org/ Downloaded from (Clontech). To obtain transient expression of hPRA1 in a mammalian cell system, DNA fragments encoding the WT hPRA1 and polypeptides comprising aa 1-164, 30-185 and 54-185 were subcloned into the pcDNA3-HA. Plasmid pGEX-5X-1/NBHRF1 was designed to express a glutathione S-transferase (GST)-BHRF1 fusion protein following subcloning of the NBHRF1 from pYYS-2 into vector pGEX-5X-1 (Amersham Pharmacia, Piscataway, N.J.).
The nucleotide sequences of all constructs were confirmed by direct DNA sequencing.
Yeast Two-Hybrid Screen -Yeast two-hybrid screening was carried out as described by Vojtek et al. (54) . Briefly, the bait plasmid, pBTM/NBHRF1, and a cDNA library of human normal foreskin keratinocytes (Clontech), in which the cDNA was fused to the GAL4-AD, were used sequentially to transform Saccharomyces cerevisiae strain L40. The resulting transformants were then plated on synthetic complete (SC) medium lacking tryptophan (Trp), uracial (Ura), leucine (Leu), lysine (Lys) and histidine (His) (SC-Trp, Ura, Leu, Lys, His) and SC-Trp, Ura, Leu, Lys as a control. His + colonies were screened for β-galactosidase activity 3 days later by colony-lift filter assay as described (54) . His + /LacZ + colonies were candidate clones of cDNAs encoding BHRF1-interacting proteins. After subsequent purification and curing processes, the cDNAs were isolated and sequenced using an ABI PRISM TM Dye
Terminator Cycle Sequencing Core Kit on the ABI 373A DNA Sequencer (Perkin-Elmer, Foster, Calif.). The resultant DNA sequences were then subjected to a BLAST search in the GenBank data base. were maintained in medium containing 400 µg/ml neomycin.
Specific Antibodies Against BHRF1-Bacterially expressed BHRF1 (49) was used to immunize BALB/c mice and produce monoclonal antibody (mAb). After several booster immunizations, mice with strong and specific immune responses were sacrificed and hybridoma cells were generated as described by Tsai et al. (58) . The antibody clone with the highest reactivity to BHRF1, 3E8, was selected by Western blot analysis and immunofluorescence assays (manuscript in preparation) 2 . BHRF1 was injected subcutaneously into the backs of rabbits to obtain a specific, polyclonal antiserum. After boosting several times, specific antisera were determined by Western blot analysis and immunofluorescence assays. DTT, 0.01 mg/ml bromophenol blue), subjected to SDS-polyacrylamide gel electrophoresis and analyzed using a PhosphorImager (Storm 840; Molecular Dynamics, Sunnyvale, Ca.). showed that all transformants could grow on SC-Trp, Ura, Leu, Lys plate (His + plate). However, the reporter genes, HIS3 and LacZ , were activated only when NBHRF1 and either hPRA1 or rPRA1 were co-expressed in the yeast cells, as demonstrated by growth of colonies on SC-Trp, Ura, Leu, Lys, His plate (His -plate) and development of blue coloration in the colony-lift filter β-galactosidase assay. This interaction-dependent activation of HIS3 and LacZ was not observed when NBHRF1 was expressed alone or when hPRA1 or rPRA1 was co-expressed with lamin as negative controls. The same results were also obtained when BHRF1of B95.8 origin (BBHRF1) was applied (Fig. 1D) . Thus, these data demonstrate that both hPRA1 and rPRA1 can interact specifically with BHRF1.
Evaluation of Protein Effects on Cell
To substantiate the interaction of PRA1 and BHRF1, a GST pull-down assay was carried out. The amount of purified GST and GST-BHRF1 fusion proteins and in vitro translated [ 35 S]-methionine-labeled hPRA1 and rPRA1 subjected for this assay are shown in figure 2A and 2B, respectively. The GST-BHRF1 fusion protein, but not GST protein, could precipitate the hPRA1 or rPRA1 protein from the translation products (Fig. 2C ), indicating that BHRF1 directly binds PRA1 in vitro. These results are consistent with those of the yeast two-hybrid assays.
To determine whether both PRA1 and BHRF1 co-localize in cells, the BHRF1-inducible clone (N27-2) was transfected along with HA-tagged rPRA1 or hPRA1 and treated with Dox to induce the expression of BHRF1 transiently. PRA1 was detected using mouse monoclonal anti-HA antibody and BHRF1 was visualized with the specific rabbit antiserum. The results were analyzed by confocal laser scanning microscopy and are shown in figure 3 . Distribution of either rPRA1 or hPRA1 was found to co-localize with BHRF1 in the transfected cells, with a perinuclear pattern of cytoplasmic staining.
Evidence of cytoplasmic co-localization supports the hypothesis that these two proteins may be associated in vivo. We carried out a co-immunoprecipitaion assay to provide further evidence that BHRF1 is associated with PRA1 in vivo. The clone N27-2 and a vector control, (Fig. 4B, lanes 6 and 10) .
This interaction was also detected in a reciprocal co-immunoprecipitation assay (Fig. 4B, lanes was confirmed by Western blotting as illustrated in figure 4A . Additionally, similar results also were observed in another mammalian cell line, 293 cells, which were co-transfected with plasmids expressing the BHRF1 and HA-tagged PRA1 (data not shown). These data indicate that BHRF1 interacts specifically with PRA1 in mammalian cells.
Identification of Domains in PRA1 which
Associate with BHRF1-In order to define the regions of PRA1 that interact with BHRF1, we studied a series of truncated rPRA1 proteins using two-hybrid assays. Protein expression by each rPRA1 mutant was determined by
Western blotting with anti-GAL4-AD antibody (Fig. 5A) . The results of the two-hybrid assays showed that only the WT rPRA1 and mutant 30-185 rPRA1, which comprised aa 30 to 185, enabled the growth of the L40 cells on SC-Trp, Ura, Leu, Lys, His plate ( Fig. 5C ) and formed a blue color in the colony-lift filter β-galactosidase assay (Fig. 5D ). This suggests that the first 29 aa of rPRA1 are not required for association with BHRF1. Mutants 1-110 rPRA1, 1-164 rPRA1, and 54-185 rPRA1 did not support cell growth (Fig. 5B-5C ). In parallel, BHRF1 of B95.8 origin (BBHRF1) was applied to this assay and also found to associate with WT rPRA1 and by each HA-tagged hPRA1 mutant and Dox-induced BHRF1 are illustrated in figure 6A , and the immunoprecipitation results are shown in figure 6B . As expected, only HA-tagged WT hPRA1 and deletion mutant 30-185 hPRA1 could be co-immunoprecipitated with BHRF1 using anti-BHRF1 antibody (Fig. 6B, lanes 8 and 16) , HA-tagged 1-164 hPRA1 and 54-185 hPRA1 were not precipitated in these assays (Fig. 6B, lanes 12 and 20) . In the reciprocal experiments, BHRF1 could be co-precipitated with HA-tagged WT hPRA1 or 30-185 hPRA1
( (Fig. 8A ). In the presence of cisplatin, the HA-tagged vector-transfected cells showed the higher survival rate if BHRF1 expression was induced (Fig. 8B, lanes 9-10, 17-18 ). These results are consistent with a previous study showing that BHRF1 conferred resistance to cisplatin-induced cell death (34, 41, 43) . Cells transfected with 1-164 hPRA1, which did not interact with BHRF1, exhibited comparable viability in the presence of BHRF1 expression (Fig. 8B, lanes 14 and 22) . However, the survival rates of cells containing WT hPRA1 or 30-185 hPRA1, both of which showed interactions with BHRF1, even in the presence of BHRF1 expression, fell off to a degree comparable to the transfectants that did not express BHRF1 (Fig. 8B, lanes 12 and 20; 16 and 24) . Similar results were obtained when apoptosis was induced by another DNA-damaging agent, mitomycin C (data not shown). Taken together, our findings provide a nice correlation between BHRF1-PRA1 interactions and reduction of BHRF1's anti -apoptotic activity.
PRA1 Does Not Interact with Bcl-2 and Exerts No Impact on the Anti-apoptotic
Activity of Bcl-2-Since BHRF1 is a viral homologue of Bcl-2, structural similarity between BHRF1 and Bcl-2 leads us to address whether Bcl-2 also interacts with PRA1. Bcl-2 was also cloned in frame with LexA-DB and tested for interaction with GAL4-AD tagged-PRA1 in the yeast two-hybrid assays (Table I) . In contrast to the reactivity shown by BHRF1, Bcl-2 was not found to associate with either hPRA1 or rPRA1 and behaved like the negative control, lamin.
Thus, although Bcl-2 is structurally and functionally similar to BHRF1, it did not interact with PRA1 in two-hybrid assays.
To determine whether PRA1 has any effect on the anti-apoptotic activity of Bcl-2, 293 cells were transiently co-transfected with plasmids expressing Bcl-2 and HA-tagged WT hPRA1. In parallel, cells were also co-transfected transiently with plasmids expressing HA-tagged WT hPRA1 and EBNA-1-tagged WT BHRF1. Since the first 18 aa of BHRF1 were required for interaction with PRA1, the mutant EBNA-1-tagged 19-191 BHRF1 was included for comparison, as well as the vector control. Protein expression of each transfectant was analyzed by Western blotting (Fig. 9A ). The transfected cells were then treated with cisplatin to induce apoptosis and assessed for cell viability. As shown in figure 9B , in the presence of cisplatin, cells expressing BHRF1 alone revealed a higher survival rate than cells containing an EBNA-1-tagged vector or expressing WT hPRA1 only (Fig. 9B, lanes 9-11, 17-19 ). Consistent with above findings, overexpressed WT hPRA1 reduced the cell viability conferred by BHRF1
to a similar level to the negative control (Fig. 9B, lanes 12 and 20) . However, Bcl-2 and 19-191 BHRF1 displayed anti-apoptotic activity and showed similar viabilities to the wild type BHRF1 but the presence of WT hPRA1 did not interfere with their ability to prevent cell death (Fig. 9B, lanes 13-16, 21-24 ). These data demonstrate that PRA1 did not affect the anti-apoptotic activity of Bcl-2, consistent with the lack of a physical interaction.
DISCUSSION
In this study, we identified a cellular protein, PRA1, which interacts specifically with EBV BHRF1 in a yeast two-hybrid system. This interaction also could be demonstrated using a GST-BHRF1 fusion protein in GST pull-down assays. Evidence of a physical association at the cellular level was provided by reciprocal co-immunoprecipitation of BHRF1 and PRA1 and co-localization in RHEK-1 and 293 cells using confocal laser scanning microscopy assays. The PRA1 protein is highly conserved, rPRA1 shares 95% amino acid identity with hPRA1 (47),
and shows similarity to a yeast gene product, Yip3p (53). In this study, we also demonstrated that both rPRA1 and hPRA1 are able to interact specifically with BHRF1 in the yeast two-hybrid system, in biochemical assays in vitro and in co-immunoprecipitation experiments.
The exact physiological function of PRA1 is still largely unknown. PRA1 was originally identified using a yeast two-hybrid screen, as a protein that associates with prenylated Rab Furthermore, functional studies showed that both WT PRA1 and 30-185 PRA1, which associated physically with BHRF1, decreased its anti-apoptotic activity, but these two proteins themselves did not promote apoptosis. However, the 1-164 PRA1 mutant was defective in BHRF1 binding and also failed to reduce the anti-apoptotic activity of BHRF1. These results strongly imply that repression of the anti-apoptotic activity of BHRF1 is dependent on the physical interaction with PRA1.
Mapping of the PRA1 binding domain(s) of BHRF1 showed that the first 18 aa (including the BH4 domain) and aa 89-142 (including the BH1 domain) were critical for interaction with PRA1. Previous studies also indicated that the BH1 domain is required for
Bcl-2 and Bcl-X L to interact with Bax (11, 60) and the BH4 domain for Bcl-2 to interact with homology. Moreover, BHRF1 has a much shorter loop region between the BH4 and BH3
domains than Bcl-2, with no significant amino acid similarity between the loop regions, suggesting the possibility of different functions for these regions (62) . Another disparity between BHRF1 and Bcl-2 is that Bcl-2 is phosphorylated in vivo and this modification has been demonstrated to be important in regulating Bcl-2 function (63, 64) . BHRF1 has been predicted to possess two potential N-glycosylation sites (32) . Thus, differences in amino acid sequence and post-translational modification could potentially explain the differential abilities of BHRF1 and Bcl-2 to interact with cellular PRA1.
It has been suggested that Bcl-2 family proteins exert their pro-or anti-apoptotic activity mainly through acting on mitochondria (22) . Previous studies showed that cellular protein 14-3-3 bound to phosphorylated Bad, a pro-apoptotic Bcl-2 homologue, and prevented it from moving to the mitochondria, thereby inhibiting apoptosis mediated by Bad (65) . Another Bcl-2 family protein, death agonist Bim, binds to LC8 dynein light chain, and is sequestered by the microtubule-associated dynein motor complex, preventing translocation to mitochondria, and eventually thwarting its pro-apoptotic activity (66). Zhu et al. stressed the importance of correct protein localization for Bcl-2 function using Bcl-2 mutants targeted to different subcellular organelle membranes (67) . Recently, a cellular reticulon family protein, RTN-x S , was found to interact with both Bcl-X L and Bcl-2 and change their subcellular localization from the mitochondria to the ER, leading to a reduction in their anti-apoptotic activities (68) .
Based on these results, we postulate that cellular protein PRA1, which is predominantly located in the Golgi apparatus, interacts with BHRF1, but not Bcl-2, and may sequester BHRF1 from the mitochondria to the Golgi apparatus, thereby hampering its anti-apoptotic activity.
However, the precise molecular mechanisms underlying the blockage of anti-apoptotic activity need to be clarified further.
To our knowledge, this is the first report indicating that a non-Bcl-2 family protein PRA1
specifically and selectively interacts with viral Bcl-2 homologue BHRF1, but not with Bcl-2, and reduces the anti-apoptotic activity of BHRF1. The molecular mechanism of BHRF1 in anti-apoptosis is still obscure. Our findings imply that selective interaction of BHRF1 with a cellular target protein, not targeted by Bcl-2, may have evolved to regulate the dynamic balance between agonists and antagonists of apoptosis. Given that the activities of BHRF1 and Bcl-2 are regulated by different mechanisms, such as various binding proteins with apparently distinct functions, BHRF1 probably acts through alternate regulatory mechanism and may function differently from Bcl-2. It is also conceivable that BHRF1 could associate with other cellular proteins (our unpublished data) 3 , and the mechanisms underlying the effects of PRA1 and the other proteins on BHRF1 activity might be totally different. to BH4, Bcl-2 homology domains 1 to 4; TM, transmembrane domain; aa, amino acids.
Molecular weight markers are indicated in kilodaltons.
